Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Study of Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Stage II-IIIB Non-small Cell Lung Cancer

NCT05387109 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT05387109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05387109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Study of Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Stage II-IIIB Non-small Cell Lung Cancer
Lead sponsor
Tang-Du Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
June 30, 2022
Completion date
April 20, 2024
Enrollment
41 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc